StockNews.com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD)

Analysts at StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a research note issued to investors on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Stock Performance

Shares of Galmed Pharmaceuticals stock opened at $0.36 on Wednesday. The business’s fifty day simple moving average is $0.36 and its 200 day simple moving average is $0.38. Galmed Pharmaceuticals has a 12 month low of $0.26 and a 12 month high of $7.80. The firm has a market capitalization of $1.83 million, a P/E ratio of -0.11 and a beta of 0.87.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.